Opko Health buys Cytochroma for up to $290mm
Executive Summary
Opko Health Inc. (vaccines, therapeutics, and diagnostics) has agreed to buy closely held renal care firm Cytochroma Inc. in a stock swap worth $100mm up front--Opko will issue 20.5mm of its common shares. Cytochroma is also entitled to up to $190mm in cash or stock earn-outs for reaching certain development and annual revenue goals.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice